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Abstract
Background: High-sensitive real-time PCR assays are routinely used to monitor HIV-1 infected subjects. Inter-assay
discrepancies have been described at the low viral load (VL) end, where clinical decisions regarding possible virological
rebound are based.
Methods: A retrospective study was performed to analyze frequencies of viral blips after transition to the COBAS
Ampliprep/COBAS TaqMan v2.0 HIV-1 assay (Taqman v2.0) in patients with prior undetectable VLs as measured with the
Roche Cobas Ampliprep Amplicor HIV-1 Monitor Test, v1.5 (Amplicor) and was evaluated in comparison to a group of
patients monitored with the Abbott Real-time HIV-1 assay (Abbott RT) during the same period of time.
Results: 85 of 373 patients with VLs below the limit of quantification with Amplicor had VLs .50 copies/mL after transition
to the TaqMan v2.0 assay. Among these 74.1% had VLs ranging from 50–499 copies/mL, 22.9% had VLs .500 copies/mL.
From 22 patients with initial Taqman v2.0 based VLs exceeding 500 copies/mL, 6 patients had VLs ,20 copies/mL after
novel VL measurement on a next visit. In our control group with VL quantification using the Abbott RT assay, only 1 patient
became detectable and showed a VL of ,40 copies/mL after new measurement.
Conclusions: Transition to the Taqman v2.0 assay was accompanied by an increase of quantifiable HIV-1 VLs in patients with
long term viral suppression under antiretroviral therapy that might be attributed to technical shortcomings of the Taqman
v2.0 assay. A high test variability at the low VL end but also beyond was observed, making meaningful clinical interpretation
of viral blips derived from different assays difficult.
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Introduction
Viral load (VL) quantification constitutes a fundamental
cornerstone of antiretroviral therapy management in HIV-1
infected subjects [1]. New, ultrasensitive real-time (RT) -PCR
assays for HIV-1 RNA quantification have been developed during
the last years including the Abbott Real Time HIV-1 assay (Abbott
RT, Abbott Diagnostics, Wiesbaden Germany) and the COBAS
Ampliprep/COBAS TaqMan HIV-1 assay (TaqMan, Roche
Diagnostics, Mannheim, Germany). Both test systems differ
significantly regarding their extraction system, primer target
region and probe design.
Shortly after the first version of the TaqMan assay (TaqMan
v1.0), which targets the gag region, was released, numerous
studies reported unusual findings including false negative or
underestimated VL measurements in patients monitored with
the TaqMan v1.0 assay [2–6]. Single point mutations in the
downstream primer of the TaqMan v1.0 assay were identified as
a leading cause for these observations [5], resulting in the
development of an upgraded TaqMan v2.0 assay using
multiplex amplification and fluorescence detection of two
distinct genomic regions, the long terminal repeat and gag
region, respectively. Furthermore, the limit of quantification
(LOQ), as defined by the manufacturer, was reduced from
40 copies/mL to 20 copies/mL. We have shown previously that
the TaqMan v2.0 and the Abbott RT assay both allowed
accurate determination of viral load levels in individuals infected
with HIV-1 isolates that were found falsely negative or
underestimated with the Roche CTM v1.0 assay [7].
Although the overall reliability and accuracy of the TaqMan
v2.0 and the Abbott RT assay, targeting the integrase region, were
found to be similar [7–9], initial reports describe a significant
variability between these assays around the LOQ [10]. We
therefore compared frequencies of viral blips in two Austrian HIV-
1 patients care centers monitoring HIV-1 VL with the Taqman
v2.0 or the Abbott RT assay, respectively.
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Methods
Plasma samples were recruited from HIV-1 infected individuals
from two Austrian HIV outpatient clinics in Salzburg (Salzburg
Center), and in Vienna (Vienna Center). Both HIV centers are
part of the Austrian HIV Cohort (AHIVCOS) and the study has
been approved by the ethics committee of the Vienna Medical
University (No. 898/2010) and the ethics committee of the
Salzburg Federal Government (No. 1159/2010), respectively.
Written informed consent was given by the patients for their
information to be stored in the hospital database and used for
research.
Both centers followed similar hospital procedures for routine
venipuncture and blood collection in ethylene diamine tetra acetic
acid (EDTA) anticoagulated tubes. Blood was collected in 10 mL
BD Vacutainer EDTA tubes and transferred within 2–4 h post
collection from the clinic site to the laboratory for further
processing. The EDTA tubes were centrifuged at arrival in the
diagnostic laboratory for 10 min at 1,100 g for plasma separation.
After centrifugation, 1 mL of plasma was transferred into
secondary tubes and stored at 220uC. On the day of analysis,
the plasma aliquots were thawed, vortexed and analyzed for viral
load.
We performed a retrospective analysis comparing both centers
in order to evaluate whether significant differences in the number
of elevated VL measurements in formerly virologically suppressed
patients after implementation of the TaqMan v2.0 assay could be
found.
On August 6, 2009 the Vienna Center switched from the Cobas
Ampliprep/ Amplicor HIV-1 Monitor Test v1.5 (Amplicor)
(Roche Diagnostics, Mannheim, Germany) to real-time PCR
technology using TaqMan v2.0. Throughout the same period of
time, the Salzburg Center used Abbott RT testing for HIV-1
quantification, which had formerly been introduced in August
2008. Inclusion criteria were chosen as follows: 1) Initiation of
ART prior to August 6, 2008, 2) $1 VL measurement in the pre
TaqMan v2.0 period from August 6, 2008 to August 5, 2009
(designated as time point 1) and all VL measurements below the
LOQ (Amplicor: ,50 copies/mL, Abbott RT: ,40 copies/mL)
and no ART changes; 3) $1 VL measurement during the
TaqMan v2.0 period from August 6, 2009 to August 5, 2010
(designated as time point 2) and no ART changes. Furthermore,
patients who reached VLs above 20 copies/mL at time point 2,
were reassessed with a new VL measurement on their next clinical
visit (designated as time point 3). For the Amplicor and the
TaqMan v2.0 assay, automated RNA extraction was performed
using the COBAS Ampliprep system. The Abbott m24 sp
automated sample preparation system was used for RNA isolation
for the Abbott RT HIV-1 assay. PCR amplification was then
performed either on the COBAS Amplicor system using the
Amplicor assay with a dynamic range from 50 to 750.000 copies/
mL, on the COBAS TaqMan 48 system using the TaqMan v2.0
assay with a dynamic range from 20 to 10.000.000 copies/mL or
on the m2000 rt Real- Time PCR system using the Abbott RT
HIV-1 assay with a dynamic range of 40 to 10.000.000 copies/
mL. Genotypic drug resistance testing was performed using the
ViroSeqH HIV-1 Genotyping System (Abbott Diagnostics).
Results
Following the switch to the TaqMan v2.0 assay in the Vienna
Center, multiple internal reports accumulated concerning an
increase of detectable VLs in patients with previous long-term
virological suppression.
In the Vienna Center, 373 of 2078 recruited HIV-1 infected
individuals met the inclusion criteria. 288 (77.2%) patients
remained with a HIV-1 VL below 50 copies/mL after
implementation of the TaqMan v2.0 assay. Due to increased
dynamic range of the TaqMan v2.0 assay 67 patients now had
quantifiable VL levels ranging from 20 to 49 copies/ml and 221
patients had VL measurements ,20 copies/ml. Interestingly for
85 subjects (22.8%) VLs .50 copies/mL were reported. Among
these patients, 63 had VLs ranging from 50–499 copies/mL
while 22 patients showed VLs .500 copies/mL (Table 1). As a
consequence all patients with VLs .20 copies/mL as measured
by TaqMan v2.0 were reassessed at time point 3. For 20
patients, VL control could not be performed. The 132 novel VL
quantifications using again TaqMan v2.0 are shown in table 2.
The majority of patients that had a VL between 20 and
499 copies/mL at time point 2 were below 20 copies/mL at
time point 3. Remarkably, in the group of patients who when
switching to TaqMan v2.0, reached at once VLs exceeding
500 copies/mL, 28.6% became undetectable after novel VL
measurement using again TaqMan v2.0, raising questions about
potential assay variability at low detection limit but also beyond
(Table 2). For three patients, additional genotypic resistance
tests were performed in response to the observed viral blips.
One resistance test revealed a new M184V mutation, another
patient had two new minor protease inhibitor mutations with no
consequences for his ongoing therapy. The third genotypic
testing originated from a salvage patient with no former
resistance testing available, so that no clinical conclusion may
be drawn in this setting. Furthermore, 6 patients underwent
subsequent ART changes as stated in their case history.
During the same time period, 288 HIV-1 infected individuals
were recruited in the Salzburg Center and 52 patients met our
inclusion criteria. For these patients, VL quantification was
performed continuously using the ABB assay and only 1 patient
became detectable (137 copies/mL) from August 2008 to August
2010. A new measurement resulted in a VL of ,40 copies/mL at
the next clinical visit. In addition a direct comparison of the
TaqMan v2.0 and the Abbott RT assay was performed at the
Salzburg Center using 77 samples originating from HIV-1 infected
subjects under ART with previous long-term virological suppres-
sion and with HIV-1RNA levels below the LOQ with at least one
of the two assays. One sample had a VL of 76 copies/ml as
measured with the Abbott RT assay but was undetectable with the
TaqMan v2.0 assay whereas 12 had a VL of .50 copies/ml with
the TaqMan v2.0 assay but were below the limit of detection with
the Abbott RT assay (data not shown).
Table 1. HIV-1 viral load (VL) measurements after the switch
to the Taqman v2.0 assay in patients under stable ART and
with VL levels below the limit of quantification (,50 copies/
ml) with the Amplicor assay for $1 year.
COBAS Ampliprep/COBAS TaqMan v2.0 HIV-1 assay
VL ,20 20–49 50–499 .500 Total
N (%) 221 (59.2) 67 (18.0) 63 (16.9) 22 (5.9) 373 (100)
VL: HIV-1 viral load levels representing copies /mL; N: number of patients;
Amplicor: Roche Cobas Ampliprep Amplicor HIV-1 Monitor Test, v1.5; TaqMan
v2.0: COBAS Ampliprep/COBAS TaqMan v2.0 HIV-1 assay.
doi:10.1371/journal.pone.0074024.t001
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Discussion
Transition from the Amplicor assay to the TaqMan v2.0 assay
in the Vienna Center was followed by an increase of quantifiable
VLs in patients with stable ART and prior successful viral
suppression, which at least in part, could not be reproduced in
subsequent VL measurements. We are aware that our findings are
not derived from repeat measurements of the same samples but
from sequential clinical visits.
The implementation of newer high-sensitive RT-PCR assays
with lower detection limits for HIV-RNA VL monitoring has been
shown to lead to increased frequency of blips [11–14]. Over the
past years, different explanations were proposed, especially
concerning probe handling. For instance, freezing plasma in situ
in a plasma preparation tube (PPT) containing a gel barrier for
separation of blood cells from plasma upon centrifugation was
associated with higher HIV-1 VL results as compared to plasma
from standard EDTA tubes when tested with the Amplicor [15,16]
and TaqMan v1.0 [17]. The disparity in quantification was more
apparent in specimens with low viremia and was associated to
transportation issues after centrifugation in PPT tubes. However,
both our centers have been continuously using standard EDTA
containing tubes without gel separation, for which increased levels
of HIV-1 RNA have not been reported [15,18]. Further, the most
obvious handling failure in clinical settings concerning standard
EDTA tubes is postponed centrifugation and plasma transfer more
than 6 h after sample collection that could lead to HIV-RNA
degradation.
A study by Garrett et al compared the size and rate of blips
between TaqMan v1.0 and 2.0 in a cohort of virologically
suppressed HIV-1 patients and found similar blip rates for both
test systems but a higher amplitude of blips with v2.0. Also a
higher proportion of blips on TaqMan v2.0 exceeding a cut-off of
200 copies/mL was observed [19]. Previous studies have also
shown that a significant percentage of HIV-1 infected patients
receiving ART with undetectable VLs as monitored with the
Abbott RT assay, tested positive with the TaqMan v2.0 assay
[7,10,20] which is in line with our findings in 77 samples with
HIV-1RNA levels below the LOQ with at least one of the two
assays. A recently published paper by Naeth et al evaluated
precision and concordance of both systems using longitudinal
specimens from HIV-1 infected patients with stable CD4+ cell
counts and found significantly higher mean VL in low viremic
samples with TaqMan v2.0 as compared with Abbott RT.
Additionally, higher coefficients of variation (37–59% with Taq-
Man v2.0 vs. 26–31% with Abbott RT) as determined by replicate
testing of three specimen samples were calculated using non-log
transformed data [10]. This phenomenon may reflect other issues
than handling procedures such as undesirable additive effects
resulting from the utilization of the same fluorescent dye for
labeling of the two TaqMan probes, targeting the LTR and gag
region, respectively. Although we are aware that our study does
not provide any mechanistically insight this technical issue might
be addressed in the future by using different fluorescent dyes for
each target and calculating VLs for each target from separate
calibration curves allowing comparison of two VL measurements
in the same sample within the same run.
The clinical significance of viral ‘‘blips’’ in previously stable
patients is still a matter of debate and remains a source of
dilemma for many clinicians. Recently, it was shown that
virological blips of .500 copies/mL were associated with
increased rebound risk, whereas no significant association was
observed for blips between 50–500 copies/mL [21]. However,
more recently, an analysis by Geretti et al showed evidence that
reliable HIV-1 detection at levels even below 50 copies/mL as
determined by Abbott RT is clinically meaningful for treatment
efficacy [22]. Furthermore, the exact etiology of ‘‘blips’’ is still
unclear, reaching from HIV rebound from reservoirs [23] or
ongoing cycles of replication [24], to random statistical
fluctuation or methodological issues, especially concerning the
high variability of RT-PCR assays at the LOQ [25]. Intermit-
tent VL elevation is also seen due to immune activation after
vaccination or in face of concomitant infection such as syphilis.
The latest version of the Department of Health and Human
Services (DHHS) guidelines as well as the AIDS Clinical Trial
Group (ACTG) recommend to define virological rebound as a
confirmed VL of .200 copies/mL [26].
In an attempt to address the socio-economic impact of our
findings, we noted that after introduction of the TaqMan v2.0
assay in the Vienna Center 132 additional VL repeat measure-
ments as well as 3 genotypic testings were required. Considering
58J per VL test, 16J per CD4 cell count, 5J per venipuncture
and 171J per genotypic resistance test, the overall cost for
additional laboratory testing reached 11000J not including the
supplementary financial burden due to ART modification. Our
very conservative estimate does also not take into account the
increased workload and time required by clinic staff as well as the
psychological stress for patients confronted with the possibility of
an emerging drug resistance and numerous adherence discussions
between patients and physicians.
In summary, we show that transition from the Amplicor assay to
a high-sensitive, dual-target RT-PCR assay (TaqMan v2.0) led to
an increased frequency of reported quantifiable VLs in patients
with long term viral suppression under ART. Although the control
group was considerably smaller than our group of interest in
Vienna, the comparison with a second center with the same
clinical standards of care using the Abbott RT assay for VL
monitoring questions the reliability of the Taqman v2.0 assay at
the lower VL end. Furthermore, the variability of VL measure-
ments in patients with VL above 500 copies/mL as determined by
Table 2. Comparison of HIV-1 viral load measurements in patients using the Taqman v2.0 assay at two different time points.
COBAS Ampliprep/COBAS TaqMan v2.0 HIV-1 assay
VL - TP3 ,20 N (%) VL - TP3=20 – 49 N (%) VL - TP3=50 – 499 N (%) VL - TP3 .500 N (%) n.d.
VL - TP2=20–49 36 (63.2%) 15 (26.3%) 5 (8.8%) 1 (1.7%) 10
VL - TP2=50–499 30 (55.6%) 9 (16.7%) 14(25.9%) 1(1.8%) 9
VL - TP2 .500 6 (28.6%) 4 (19.0%) 6 (28.6%) 5 (23.8%) 1
VL-TP2; HIV-1 viral load (copies/ml) at time point 2; VL-TP3; HIV-1 viral load (copies/ml) at time point 3; N: number of patients; n.d.: not determined; TaqMan v2.0: COBAS
Ampliprep/COBAS TaqMan v2.0 HIV-1 assay.
doi:10.1371/journal.pone.0074024.t002
HIV-1 Low Level Viremia and Roche TaqMan v2.0
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TaqMan v2.0 was surprising and constitutes an additional matter
of concern. For clinicians interpretation of single detectable HIV
VLs especially when longitudinal data are derived from different
assays is very difficult and should not lead to immediate genotypic
testing or therapy intensification.
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